SG11201906767XA - Estrogen receptor modulators - Google Patents
Estrogen receptor modulatorsInfo
- Publication number
- SG11201906767XA SG11201906767XA SG11201906767XA SG11201906767XA SG11201906767XA SG 11201906767X A SG11201906767X A SG 11201906767XA SG 11201906767X A SG11201906767X A SG 11201906767XA SG 11201906767X A SG11201906767X A SG 11201906767XA SG 11201906767X A SG11201906767X A SG 11201906767XA
- Authority
- SG
- Singapore
- Prior art keywords
- cambridge
- astrazeneca
- building
- international
- owg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) Iiiiionoilloionliol OMMI 11100111001110#011 (10) International Publication Number WO 2018/138303 Al WIPO I PCT (51) International Patent Classification: CO7D 471/04 (2006.01) A61K 31/506 (2006.01) A61P 35/00 (2006.01) A61K 31/501 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/EP2018/052040 (22) International Filing Date: 29 January 2018 (29.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/451,971 30 January 2017 (30.01.2017) US 62/523,695 22 June 2017 (22.06.2017) US 62/560,304 19 September 2017 (19.09.2017) US 62/592,485 30 November 2017 (30.11.2017) US (71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). (72) Inventors: SCOTT, James, Stewart; AstraZeneca Dar- win Building, Cambridge Science Park, Milton Road Cam- bridge CB4 OWG (GB). MOSS, Thomas, Andrew; As- traZeneca Darwin Building, Cambridge Science Park, Mil- ton Road Cambridgeshire CB4 OWG (GB). HUGHES, Samantha, Jayne; AstraZeneca Darwin Building, Cam- bridge Science Park, Milton Road, Cambridge Cam- bridgeshire CB4 OWG (GB). NISSINK, Johannes, Wil- helmus, Maria; AstraZeneca, Darwin Building Cambridge Science Park, Milton Road, Cambridge Canbridgeshire CB4 OWG (GB). BARLAAM, Bernard, Christophe; As- traZeneca, Darwin Building Cambridge Science Park, Mil- ton Road, Cambridge Cambridgeshire CB4 OWG (GB). YANG, Bin; AstraZeneca 35 Gatehouse Drive, Waltham, MA 02451 (US). (74) Agent: COOK, Andrew, James; AstraZeneca Milstein Building, Cambridge Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: — with international search report (Art. 21(3)) (54) Title: ESTROGEN RECEPTOR MODULATORS R 1 \ D—E N/ \ Rio A , Q R9 \ R 20 R 17 N R, G 2 H R 18 R 3 / R R 7 (I) \" (57) : The specification relates to compounds of Formula (I): (I) Sand to pharmaceutically acceptable salts thereof, to processes ,„.,„ and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders. 18/ 138303 Al
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451971P | 2017-01-30 | 2017-01-30 | |
| US201762523695P | 2017-06-22 | 2017-06-22 | |
| US201762560304P | 2017-09-19 | 2017-09-19 | |
| US201762592485P | 2017-11-30 | 2017-11-30 | |
| PCT/EP2018/052040 WO2018138303A1 (en) | 2017-01-30 | 2018-01-29 | Estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906767XA true SG11201906767XA (en) | 2019-08-27 |
Family
ID=61223883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906767XA SG11201906767XA (en) | 2017-01-30 | 2018-01-29 | Estrogen receptor modulators |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10221173B2 (en) |
| EP (2) | EP3494116B1 (en) |
| JP (1) | JP6951451B2 (en) |
| KR (1) | KR102246668B1 (en) |
| CN (1) | CN110214140B (en) |
| AU (1) | AU2018211495B2 (en) |
| BR (1) | BR112019015389A2 (en) |
| CA (1) | CA3050337A1 (en) |
| CL (1) | CL2019001991A1 (en) |
| CO (1) | CO2019008941A2 (en) |
| CR (1) | CR20190379A (en) |
| CY (1) | CY1122731T1 (en) |
| DK (1) | DK3494116T3 (en) |
| DO (1) | DOP2019000183A (en) |
| EC (1) | ECSP19062381A (en) |
| ES (2) | ES2931320T3 (en) |
| HU (1) | HUE047761T2 (en) |
| IL (1) | IL268263B (en) |
| JO (1) | JOP20190183B1 (en) |
| LT (1) | LT3494116T (en) |
| MA (1) | MA52555A (en) |
| MX (1) | MX2019008438A (en) |
| MY (1) | MY196317A (en) |
| NI (1) | NI201900080A (en) |
| PE (1) | PE20191500A1 (en) |
| PH (1) | PH12019501724A1 (en) |
| PL (1) | PL3494116T3 (en) |
| PT (1) | PT3494116T (en) |
| RS (1) | RS59770B1 (en) |
| SG (1) | SG11201906767XA (en) |
| SI (1) | SI3494116T1 (en) |
| TN (1) | TN2020000009A1 (en) |
| TW (1) | TWI794205B (en) |
| UA (1) | UA125043C2 (en) |
| WO (1) | WO2018138303A1 (en) |
| ZA (1) | ZA201904696B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102479822B1 (en) | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | Selective estrogen receptor degraders and their uses |
| MD3555097T2 (en) | 2016-12-16 | 2022-12-31 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of Janus kinases |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
| WO2021055749A1 (en) * | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
| CN115557920B (en) * | 2022-09-22 | 2024-02-20 | 吉林奥来德光电材料股份有限公司 | Light-emitting auxiliary material, preparation method thereof and organic electroluminescent device |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EE05405B1 (en) | 2000-08-10 | 2011-04-15 | Pharmacia Italia S.P.A. | Bit clopazoles acting as kinase inhibitors, process for their preparation, use and pharmaceutical compositions containing them |
| WO2005111208A1 (en) * | 2004-04-27 | 2005-11-24 | Chugai Seiyaku Kabushiki Kaisha | Method of proliferating plasma cell |
| WO2006101434A1 (en) | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| FR2884252B1 (en) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY |
| AR058223A1 (en) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | A COMMITTEE OF PIRAZOLOISOQUINOLINE DERIVATIVES, A PROCEDURE FOR THE PREPARATION OF SUCH COMPOUND AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND |
| JP2010505961A (en) | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | Kinase inhibitor |
| CA2763485C (en) | 2009-05-27 | 2018-05-15 | Neil Almstead | Methods for treating cancer and non-neoplastic conditions |
| WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| US20120157402A1 (en) * | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| EP2791133B1 (en) | 2011-12-14 | 2019-04-17 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
| WO2014191726A1 (en) * | 2013-05-28 | 2014-12-04 | Astrazeneca Ab | Chemical compounds |
| KR20160021281A (en) | 2013-06-19 | 2016-02-24 | 세라곤 파마슈티컬스, 인크. | Azetidine estrogen receptor modulators and uses thereof |
| BR112015031903A8 (en) | 2013-06-19 | 2019-12-31 | Seragon Pharmaceuticals Inc | compound, pharmaceutically acceptable salt, pharmaceutical composition and use of a compound |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
| JP2017538727A (en) | 2014-12-18 | 2017-12-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| SG10202100799PA (en) | 2014-12-18 | 2021-03-30 | Hoffmann La Roche | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| JP6768711B2 (en) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Heterocyclic estrogen receptor modulator and its use |
| CA2988620A1 (en) | 2015-06-16 | 2016-12-22 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
| CN106518768B (en) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | Acrylic acid derivative, preparation method and medical application thereof |
| RU2745742C1 (en) | 2015-10-01 | 2021-03-31 | Олема Фармасьютикалз, Инк. | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
| EP3374356A1 (en) | 2015-11-09 | 2018-09-19 | H. Hoffnabb-La Roche Ag | Tetrahydronaphthalene estrogen receptor modulators and uses thereof |
| US10519148B2 (en) | 2015-11-12 | 2019-12-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| CN107428721B (en) | 2015-12-22 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | Benzopiperidine derivative, preparation method and medical application thereof |
| WO2017174757A1 (en) | 2016-04-08 | 2017-10-12 | F. Hoffmann-La Roche Ag | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| JP7064772B2 (en) | 2016-05-06 | 2022-05-11 | ザビエル・ユニバーシティ・オブ・ルイジアナ | Selective Estrogen Receptor Down Regulator (SERDS) |
| CN109415361B (en) | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | Acrylic acid derivative, preparation method thereof and application thereof in medicine |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN107814798B (en) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-substituted acrylic acid compound and preparation method and application thereof |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| SG11201903182XA (en) | 2016-10-24 | 2019-05-30 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| BR102016024814A2 (en) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | Compound, Compounding Process, Pharmaceutical Composition, Compound Use, and Method of Treatment of Psychiatric Disorders and / or Sleep Disorders |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| PL3555105T3 (en) | 2016-12-16 | 2021-05-17 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
| CN110291072A (en) | 2016-12-16 | 2019-09-27 | 巴斯夫欧洲公司 | Agricultural chemical compound |
| MD3555097T2 (en) | 2016-12-16 | 2022-12-31 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of Janus kinases |
| EP3555062A1 (en) | 2016-12-16 | 2019-10-23 | Reata Pharmaceuticals, Inc. | Pyrimidine tricyclic enone derivatives for inhibition of ror gamma and other uses |
| JP6637641B1 (en) | 2016-12-16 | 2020-01-29 | ファイザー・インク | GLP-1 receptor agonists and uses thereof |
| AU2018212593B2 (en) | 2017-01-30 | 2022-05-19 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as Rho- kinase inhibitors |
-
2018
- 2018-01-29 CA CA3050337A patent/CA3050337A1/en active Pending
- 2018-01-29 US US15/881,962 patent/US10221173B2/en active Active
- 2018-01-29 AU AU2018211495A patent/AU2018211495B2/en active Active
- 2018-01-29 SG SG11201906767XA patent/SG11201906767XA/en unknown
- 2018-01-29 ES ES19203383T patent/ES2931320T3/en active Active
- 2018-01-29 ES ES18705097T patent/ES2766249T3/en active Active
- 2018-01-29 SI SI201830022T patent/SI3494116T1/en unknown
- 2018-01-29 MY MYPI2019004298A patent/MY196317A/en unknown
- 2018-01-29 CR CR20190379A patent/CR20190379A/en unknown
- 2018-01-29 TN TNP/2020/000009A patent/TN2020000009A1/en unknown
- 2018-01-29 EP EP18705097.6A patent/EP3494116B1/en active Active
- 2018-01-29 PL PL18705097T patent/PL3494116T3/en unknown
- 2018-01-29 LT LTEP18705097.6T patent/LT3494116T/en unknown
- 2018-01-29 RS RS20200018A patent/RS59770B1/en unknown
- 2018-01-29 MA MA052555A patent/MA52555A/en unknown
- 2018-01-29 PE PE2019001434A patent/PE20191500A1/en unknown
- 2018-01-29 BR BR112019015389-6A patent/BR112019015389A2/en active Search and Examination
- 2018-01-29 TW TW107103088A patent/TWI794205B/en active
- 2018-01-29 JP JP2019538615A patent/JP6951451B2/en active Active
- 2018-01-29 EP EP19203383.5A patent/EP3689873B1/en active Active
- 2018-01-29 UA UAA201909412A patent/UA125043C2/en unknown
- 2018-01-29 KR KR1020197025253A patent/KR102246668B1/en active IP Right Grant
- 2018-01-29 WO PCT/EP2018/052040 patent/WO2018138303A1/en unknown
- 2018-01-29 JO JOP/2019/0183A patent/JOP20190183B1/en active
- 2018-01-29 PT PT187050976T patent/PT3494116T/en unknown
- 2018-01-29 DK DK18705097.6T patent/DK3494116T3/en active
- 2018-01-29 HU HUE18705097A patent/HUE047761T2/en unknown
- 2018-01-29 MX MX2019008438A patent/MX2019008438A/en unknown
- 2018-01-29 CN CN201880008715.8A patent/CN110214140B/en active Active
-
2019
- 2019-01-31 US US16/263,683 patent/US10590132B2/en active Active
- 2019-07-15 CL CL2019001991A patent/CL2019001991A1/en unknown
- 2019-07-16 DO DO2019000183A patent/DOP2019000183A/en unknown
- 2019-07-17 ZA ZA2019/04696A patent/ZA201904696B/en unknown
- 2019-07-25 IL IL268263A patent/IL268263B/en unknown
- 2019-07-26 PH PH12019501724A patent/PH12019501724A1/en unknown
- 2019-07-26 NI NI201900080A patent/NI201900080A/en unknown
- 2019-08-16 CO CONC2019/0008941A patent/CO2019008941A2/en unknown
- 2019-08-28 EC ECSENADI201962381A patent/ECSP19062381A/en unknown
-
2020
- 2020-01-08 CY CY20201100014T patent/CY1122731T1/en unknown
- 2020-01-29 US US16/775,781 patent/US11046689B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SG11201906767XA (en) | Estrogen receptor modulators | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201408324QA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201908729UA (en) | Phenyl derivatives as pge2 receptor modulators | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201908097YA (en) | Pyrimidine derivatives as pge2 receptor modulators | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form |